Posts Tagged ‘FDA Testosterone’

September 20, 2014 @ 11:21 am | Category:News | Tags: ,

An FDA Advisory Panel met on September 17-18 to evaluate the benefits and risks of prescription testosterone supplements, including AndroGel, Axiron, Fortesta and other drugs in this class. The Panel concluded that there is insufficient evidence to support the manufacturers’ claims that the supplements treat diminishing testosterone levels. The Panel also recommended further study of […]

(Read more ...)